Ocugen Licenses OCU400 to Roots Pharmaceutical for MENA Market
Event summary
- Ocugen licenses OCU400, a modifier gene therapy for retinitis pigmentosa, to Roots Pharmaceutical for exclusive rights in the Middle East and North Africa (MENA).
- Deal includes upfront license fee and initial development payments up to $4 million, potential sales milestones up to $255 million, and 22% royalties on net sales.
- Ocugen will manufacture and supply OCU400 under a related supply agreement.
- Retinitis pigmentosa prevalence in MENA is estimated to be 10 to 20 times higher than in the U.S. and EU.
- Phase 3 liMeliGhT clinical trial for OCU400 expected to read out topline data in Q1 2027.
The big picture
This licensing agreement expands Ocugen's commercial reach into a region with high disease prevalence and significant unmet need. The deal underscores the strategic importance of regional partnerships in the gene therapy space, particularly for addressing rare diseases with high geographic variability in prevalence. The potential $255 million in sales milestones and 22% royalties highlight the financial stakes of successfully commercializing OCU400 in MENA.
What we're watching
- Regulatory Milestones
- Whether OCU400's Phase 3 trial results in Q1 2027 will support global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe.
- Commercial Execution
- How Roots Pharmaceutical will build the diagnosis-to-treatment pathway required for gene therapy across MENA markets.
- Revenue Potential
- The pace at which OCU400 achieves commercial success in MENA, given the region's high prevalence of retinitis pigmentosa and substantial unmet medical need.
Related topics
